Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Eur Urol. 2019 Oct 20;77(3):333–341. doi: 10.1016/j.eururo.2019.09.036

Fig. 5 –

Fig. 5 –

Kaplan-Meier curves for time to PSA progression on first-line AR pathway inhibitor (ARPI) therapy. Median time to PSA progression: CDK12 3.6 mo, HRD 3.3 mo, TP53 5.6 mo, and other 7.4 mo. Overall p = 0.012. CDK12 versus HRD p = 0.47, CDK12 versus TP53 p = 0.069, CDK12 versus other p = 0.0023, HRD versus TP53 p = 0.063, HRD versus other p = 0.022, and TP53 versus other p = 0.67. The greatest difference was between the CDK12 and the other cohort (3.6 vs 7.4 mo, p = 0.0023). The p values are based on log rank test.

AR = androgen receptor; CDK12 = cyclin-dependent kinase 12; HRD = homologous recombination deficiency; PSA = prostate-specific antigen.